Janux Therapeutics (JANX) Projected to Release Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.26) per share and revenue of $19.0750 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million. On average, analysts expect Janux Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Janux Therapeutics Trading Down 0.3%

Shares of JANX stock opened at $14.96 on Thursday. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The stock has a market cap of $912.26 million, a price-to-earnings ratio of -8.13 and a beta of 2.52. The stock has a 50-day moving average of $14.88 and a 200-day moving average of $14.36.

Insider Transactions at Janux Therapeutics

In related news, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at approximately $457,265.90. The trade was a 5.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in JANX. Janus Henderson Group PLC lifted its holdings in shares of Janux Therapeutics by 13.8% in the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock valued at $73,850,000 after purchasing an additional 649,341 shares in the last quarter. State Street Corp lifted its stake in Janux Therapeutics by 103.8% during the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock valued at $53,185,000 after acquiring an additional 1,962,486 shares in the last quarter. Vanguard Group Inc. lifted its stake in Janux Therapeutics by 10.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock valued at $59,074,000 after acquiring an additional 227,676 shares in the last quarter. Prosight Management LP boosted its holdings in Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after acquiring an additional 1,527,173 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its holdings in Janux Therapeutics by 10.7% during the 4th quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock worth $26,971,000 after acquiring an additional 188,326 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analysts Set New Price Targets

JANX has been the subject of a number of recent analyst reports. Guggenheim decreased their target price on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and dropped their price objective for the company from $29.00 to $14.00 in a research note on Monday, April 20th. Evercore set a $22.00 target price on shares of Janux Therapeutics in a research report on Monday, May 11th. Finally, Truist Financial reissued a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.08.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.